BioSpace News Archive

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for third quarter 2021 after the close of trading on Nov. 4, 2021.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021.

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), announced that it will report its financial results for the third quarter and first nine-month period ending September 30, 2021, on Thursday, November 4, 2021, after the close of the US market.

Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and six months ended September 30, 2021.

A committee of experts advising the Food and Drug Administration met on Oct 26 and voted 17 to 0, with one abstention, to recommend authorizing the Pfizer-BioNTech coronavirus vaccine for children 5 to 11 years old.

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceuticals Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), “Sun Pharma” including its subsidiaries and/or associate companies) is pleased to announce PrILUMYA™ (tildrakizumab injection).

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata,” “us,” “our,” or the “Company”), today announced that the company has received an equity investment from the Cystic Fibrosis Foundation (“CF Foundation”) with participation from Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (collectively, “Innoviva”).